Galderma's Relfydess™ receives European approval for use, expanding treatment options.
Galderma's Relfydess™ (RelabotulinumtoxinA) has received a positive decision for use in Europe, expanding its treatment options for patients. This marks a significant milestone for Galderma, which specializes in dermatology and aesthetics. The European Commission's positive decision follows the European Medicines Agency's Committee for Medicinal Products for Human Use's recommendation.
July 30, 2024
3 Articles